Form 4: CARGO Therapeutics Director Jane Henderson Granted 25,000 Stock Options

CARGO Therapeutics, Inc. Director Jane Henderson was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next annual meeting.

Summary

• Jane Henderson, a Director of CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options.
• The transaction date for this grant was June 18, 2025.
• The exercise price for these stock options is $4.35 per share.
• The options are scheduled to vest 100% on the earlier of the one-year anniversary of June 18, 2025, or the next Annual Meeting following June 18, 2025, contingent on Ms. Henderson's continued service to the Issuer.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Jane Henderson beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive. The grant of stock options to a director is a standard practice that aligns management's interests with shareholders, which is generally viewed favorably. It does not indicate any immediate negative operational or financial issues.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $4.35 provides a clear benchmark for the value at which the options can be converted into common stock.

Risks

• The value of the stock options is dependent on the future performance of CARGO Therapeutics' stock price; if the stock price does not exceed the exercise price, the options may expire worthless.
• The vesting of the options is subject to the reporting person's continued service to the Issuer, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options are subject to a future vesting schedule, which will occur on the earlier of the one-year anniversary of the grant date (June 18, 2025) or the next Annual Meeting following the grant date, contingent on continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It reflects a standard practice of compensating directors with equity to align their interests with long-term shareholder value, particularly in the biotechnology or pharmaceutical sector where long-term development cycles are prevalent.

Comparison to Industry Standards

• The grant of stock options to directors is a common compensation practice in publicly traded companies, including those in the biotechnology sector like CARGO Therapeutics, Inc.
• The vesting schedule (one year or next annual meeting) is a typical short-to-medium term vesting period for director equity grants, aiming to retain talent and incentivize performance over a reasonable timeframe.
• The exercise price of $4.35 is set at the market price on the grant date, which is standard for incentive stock options.

Corporate Governance

Related Party Transactions

• Grant of 25,000 stock options by CARGO Therapeutics, Inc. to Jane Henderson, a Director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive step towards aligning management incentives with shareholder returns, potentially fostering long-term value creation.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can influence overall company culture and retention of key personnel.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the next Annual Meeting following June 18, 2025, subject to continued service.
• Jane Henderson may exercise the vested options at any time before the expiration date of June 17, 2035.

Key Dates

Keywords

CARGO Therapeutics, CRGX, SEC Form 4, stock options, insider transaction, director compensation, equity grant, beneficial ownership